CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...